655 related articles for article (PubMed ID: 33527753)
21. Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone.
Arcani R; Venton G; Colle J; Suchon P; Ivanov V; Mercier C; Farnault L; Roche P; Lafage M; Brunet C; Azouza W; Pourroy B; Fanciullino R; Costello R
Eur J Haematol; 2019 Oct; 103(4):385-392. PubMed ID: 31319001
[TBL] [Abstract][Full Text] [Related]
22. Lenalidomide, bortezomib and dexamethasone followed by tandem- autologous stem cell transplantation is an effective treatment modality for multi-hit multiple myeloma.
Tang S; Lu Y; Zhang P; Chen D; Liu X; Du X; Cao J; Ye P; Chen L; Li S; Sha K; Zhuang XX; Xie Y; Wu X; Pei R
Leuk Res; 2021 Nov; 110():106710. PubMed ID: 34619433
[TBL] [Abstract][Full Text] [Related]
23. Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials.
Kauer J; Freundt EP; Schmitt A; Weinhold N; Mai EK; Müller-Tidow C; Goldschmidt H; Raab MS; Kriegsmann K; Sauer S
BMC Cancer; 2023 Nov; 23(1):1132. PubMed ID: 37990162
[TBL] [Abstract][Full Text] [Related]
24. [Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma].
Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gal'tseva IV; Kuz'mina LA; Akhundova FM; Kalinin NN; Gretsov EM; Parovichnikova EN; Savchenko VG
Ter Arkh; 2012; 84(7):35-41. PubMed ID: 23038970
[TBL] [Abstract][Full Text] [Related]
25. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma.
Baz RC; Shain KH; Hussein MA; Lee JH; Sullivan DM; Oliver EF; Nardelli LA; Nodzon LA; Zhao X; Ochoa-Bayona JL; Nishihori T; Dalton WS; Alsina M
Am J Hematol; 2014 Jan; 89(1):62-7. PubMed ID: 24030918
[TBL] [Abstract][Full Text] [Related]
27. Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
Sunami K; Matsumoto M; Fuchida SI; Omoto E; Takamatsu H; Adachi Y; Choi I; Fujishima N; Kiguchi T; Miyamoto T; Maeda A; Suzumiya J; Yamamura R; Nagafuji K; Nakazato T; Kuroda Y; Yujiri T; Takamatsu Y; Harada M; Akashi K
Int J Clin Oncol; 2019 Aug; 24(8):966-975. PubMed ID: 30937622
[TBL] [Abstract][Full Text] [Related]
28. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.
Stadtmauer EA; Pasquini MC; Blackwell B; Hari P; Bashey A; Devine S; Efebera Y; Ganguly S; Gasparetto C; Geller N; Horowitz MM; Koreth J; Knust K; Landau H; Brunstein C; McCarthy P; Nelson C; Qazilbash MH; Shah N; Vesole DH; Vij R; Vogl DT; Giralt S; Somlo G; Krishnan A
J Clin Oncol; 2019 Mar; 37(7):589-597. PubMed ID: 30653422
[TBL] [Abstract][Full Text] [Related]
29. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial.
Goldschmidt H; Mai EK; Dürig J; Scheid C; Weisel KC; Kunz C; Bertsch U; Hielscher T; Merz M; Munder M; Lindemann HW; Hügle-Dörr B; Tichy D; Giesen N; Hose D; Seckinger A; Huhn S; Luntz S; Jauch A; Elmaagacli A; Rabold B; Fuhrmann S; Brossart P; Goerner M; Bernhard H; Hoffmann M; Hillengass J; Raab MS; Blau IW; Hänel M; Salwender HJ;
Leukemia; 2020 Jul; 34(7):1853-1865. PubMed ID: 32034285
[TBL] [Abstract][Full Text] [Related]
30. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
31. Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma.
Mori Y; Takizawa J; Katsuoka Y; Takezako N; Nagafuji K; Handa H; Kuroda J; Sunami K; Kamimura T; Ogawa R; Kikushige Y; Harada M; Akashi K; Miyamoto T;
Cancer Sci; 2024 Jun; 115(6):2002-2011. PubMed ID: 38498976
[TBL] [Abstract][Full Text] [Related]
32. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
33. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
34. Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study.
Horvath N; Spencer A; Kenealy M; Joshua D; Campbell PJ; Lee JJ; Hou J; Qiu L; Kalff A; Khong T; Londhe A; Siggins S; van Kooten Losio M; Eisbacher M; Prince HM
Leuk Lymphoma; 2019 Sep; 60(9):2122-2133. PubMed ID: 30777794
[TBL] [Abstract][Full Text] [Related]
35. Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.
Joseph NS; Kaufman JL; Dhodapkar MV; Hofmeister CC; Almaula DK; Heffner LT; Gupta VA; Boise LH; Lonial S; Nooka AK
J Clin Oncol; 2020 Jun; 38(17):1928-1937. PubMed ID: 32298201
[TBL] [Abstract][Full Text] [Related]
36. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
37. Feasibility of six cycles of lenalidomide-based triplet induction before stem cell collection for newly diagnosed transplant-eligible multiple myeloma.
Yoshihara S; Yoshihara K; Shimizu Y; Imado T; Takatsuka H; Kawamoto H; Misawa M; Ifuku H; Ohe Y; Okada M; Fujimori Y
Hematology; 2021 Dec; 26(1):388-392. PubMed ID: 34000225
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy-A Single Institution Experience.
Tanimura A; Hirai R; Nakamura M; Takeshita M; Togano T; Sekine R; Hagiwara S; Miwa A
Gan To Kagaku Ryoho; 2020 May; 47(5):789-796. PubMed ID: 32408321
[TBL] [Abstract][Full Text] [Related]
39. Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.
Li J; Bao L; Xia Z; Wang S; Zhou X; Ding K; Zhang W; Yang W; Li B; Fu C; Chen B; Hua L; Wang L; Luo J; Yang Y; Xu T; Wang W; Huang Y; Wu G; Liu P
Ann Hematol; 2020 Nov; 99(11):2589-2598. PubMed ID: 32892275
[TBL] [Abstract][Full Text] [Related]
40. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.
Mai EK; Bertsch U; Dürig J; Kunz C; Haenel M; Blau IW; Munder M; Jauch A; Schurich B; Hielscher T; Merz M; Huegle-Doerr B; Seckinger A; Hose D; Hillengass J; Raab MS; Neben K; Lindemann HW; Zeis M; Gerecke C; Schmidt-Wolf IG; Weisel K; Scheid C; Salwender H; Goldschmidt H
Leukemia; 2015 Aug; 29(8):1721-9. PubMed ID: 25787915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
